ProMetic Life Sciences Inc. (PLI) Scheduled to Post Earnings on Monday
ProMetic Life Sciences Inc. (TSE:PLI) is scheduled to be posting its quarterly earnings results after the market closes on Monday, August 14th.
Shares of ProMetic Life Sciences Inc. (TSE:PLI) traded down 0.314% during mid-day trading on Wednesday, reaching $1.585. 70,580 shares of the company’s stock were exchanged. The stock’s market cap is $1.06 billion. ProMetic Life Sciences Inc. has a one year low of $1.45 and a one year high of $3.24. The company has a 50 day moving average price of $1.64 and a 200-day moving average price of $2.04.
PLI has been the topic of a number of analyst reports. Canaccord Genuity decreased their price objective on shares of ProMetic Life Sciences from C$4.75 to C$4.50 and set a “buy” rating on the stock in a research report on Monday, June 19th. Royal Bank Of Canada restated an “outperform” rating on shares of ProMetic Life Sciences in a research report on Wednesday, May 24th. Finally, Scotiabank decreased their price objective on shares of ProMetic Life Sciences from C$4.75 to C$4.00 and set an “outperform” rating on the stock in a research report on Friday, July 7th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of C$4.37.
In other ProMetic Life Sciences news, Director Louise Ménard sold 82,202 shares of the business’s stock in a transaction dated Monday, July 10th. The shares were sold at an average price of C$1.60, for a total value of C$131,523.20. Insiders acquired 28,424 shares of company stock worth $56,809 in the last 90 days.
About ProMetic Life Sciences
ProMetic Life Sciences Inc, a biopharmaceutical company, develops bioseparations, plasma-derived therapeutics, and small-molecule therapeutic products. The company offers its technology platform for large-scale drug purification, drug development, proteomics, and the elimination of pathogens; and develops small molecule therapeutic products targeting unmet medical needs in the fields of fibrosis, autoimmune disease/inflammation, and cancer.
Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.